For example, by performing intermittent dosing strategies bypassing cardiovascular toxicity,321,322 by specifically inhibiting only the TGFβ1 isoform that has the strongest link with cancer progression,282 or by selecting cancer patients for treatment with a mesenchymal phenotype and high TGFβ activity that are likely to benefit most from the TGFβ targeting.22,250. Here, TGFB1 is linked to cancer.